bictegravir/emtricitabine/tenofovir vs valganciclovir
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and valganciclovir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Recommendation: Your healthcare provider should check your kidney function regularly to make sure the drugs are being processed safely.
Biktarvy
Valcyte
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Valganciclovir is an antiviral medicine. It helps prevent cytomegalovirus (CMV) disease in children who have received kidney or heart transplants.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
This medicine prevents CMV disease in children after they get a kidney or heart transplant. CMV is a virus that can cause problems in people with weakened immune systems. Valganciclovir helps to stop the virus from growing and causing illness.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Valganciclovir changes into ganciclovir in your body. Ganciclovir stops CMV from making copies of itself. This helps to prevent or treat CMV infections.
- • Diarrhea
- • Nausea
- • Headache
- • Diarrhea
- • Fever
- • Upper respiratory infection
- • Urinary tract infection
- • Vomiting
No adverse event reports.
- CMV infection 1,756
- Low white blood cell count 1,096
- Fever 940
- Diarrhea 916
- Low white blood cell count 914
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
Valganciclovir can cause serious side effects, including: - Lowered blood cell counts. This can lead to infections and bleeding. - Fertility problems in both men and women. - Birth defects if taken during pregnancy. - Cancer. Talk to your doctor about these risks.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
This medicine can cause birth defects. Do not take it if you are pregnant or plan to become pregnant. Breastfeeding is not recommended while taking this medicine.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
Compare valganciclovir with
How to Read This bictegravir/emtricitabine/tenofovir vs valganciclovir Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while valganciclovir sits within the Antiviral (Nucleoside Analog) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while valganciclovir has 5,622. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to both medicines use the same exit route in the kidneys to leave your body. this could cause the levels of these drugs to increase in your system.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between bictegravir/emtricitabine/tenofovir and valganciclovir - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.